AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03281668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Description: Each training session for High Intensity Interval Training will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
Study NCT02106286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Study NCT02361450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retrograde Colonic Irrigation
Study NCT02361450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Study NCT02361450 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study NCT01516970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Ritonavir (DRV/r)
Description: Darunavir (DRV) type=exact number, unit=mg, number=800, form=tablet, route=oral use. Tablet is taken once a day, for 28 days; Ritonavir (r) type=exact number, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
Study NCT01516970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir in fixed combination with Ritonavir
Description: type=exact number, unit=mg, number=400/100, form=tablet, route=oral use. Tablet is taken once or twice a day, for at least 28 days and a maximum of 30 days.
Study NCT01516970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: type=exact number, unit=mg, number=250, form=tablet, route=oral use. Tablet is taken twice a day, for at least 28 days and a maximum of 30 days.
Study NCT01516970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NRTIs
Description: The NRTIs (including tenofovir/emtricitabine \[Truvada\], lamivudine/zidovudine \[Combivir\]) will be administered as per the individual Summary of Product Characteristics (SmPCs) at the discretion of either the treating physician or Investigator.
Study NCT01516970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs
Description: The NRTIs (including tenofovir/emtricitabine \[Truvada\], lamivudine/zidovudine \[Combivir\]) will be administered as per the individual Summary of Product Characteristics (SmPCs) at the discretion of either the treating physician or Investigator.
Study NCT01516970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: type=exact number, unit=mg, number=600, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
Study NCT00956774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HSG with acorn-tipped cannula
Description: Use of acorn-tipped cannula for HSG to evaluate tubal patency
Study NCT00956774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HSG with cervical vacuum cup
Description: cup placed over cervix to create vacuum pressure.
Study NCT00956774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HSG with balloon catheter
Description: balloon inserted via catheter into cervic for dilation.
Study NCT02667275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Solution
Study NCT02667275 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Solution
Description: Placebo
Study NCT01487642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard 15-minute telephone counselling
Description: Subjects in arm 1 will benefit from a standard 15-minute telephone counselling session with a professional adviser which resembles a normal call to the national Quit-line. The telephone counselling will be reactive, thus the smoker initiates the call to a designated number to receive advice and information based on the needs and wishes of this particular smoker. Participants can receive self-help materials and information on other smoking cessation services if they wish.
Study NCT01487642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proactive telephone counselling
Description: subjects in arm 2 will benefit from of five 15-minute calls from a professional adviser. Similar to the standard reactive telephone counselling, the proactive counselling will be a personal discussion and advice based on the needs and wishes of the particular participant. Together, the participant and adviser will determine a cessation date and schedule one call 3-7 days before the cessation date, one call immediately after the cessation date and three additional calls on days 3, 10 and 24, respectively, post-cessation.
Study NCT01487642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interactive web-based smoking cessation programme
Description: Subjects in arm 3 will benefit from a tailored and interactive web-based smoking cessation programme. Besides interactive and personalised information generated on the webpage, the participant will receive by e-mail and SMS tailored feedback messages based on the particular profile of the participant on particular dates as well as topics during the cessation period depending on how well the cessation is proceeding.
Study NCT01487642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-help material
Description: Participants receives self-help materials and on request information on other smoking cessation services if they wish.
Study NCT01756040 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lactulose -rhamnose solution
Description: Measurement of intestinal permeability by use of mon- digestible sugars known not to cross the intestinal barrier in normal healthy intestinal tissue
Study NCT02834169 — intervention group
Intervention type: OTHER
Intervention: Non interventional
Description: Data collection
Study NCT00130702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: gefitinib (Iressa) at a dose of 750 mg, once per day
Study NCT02538016 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tolvaptan
Study NCT04543799 — intervention group
Intervention type: DEVICE
Intervention: polysomnography, actigraphy, questionnaires
Description: sleep quality recording
Study NCT01110616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: MK3134, 25 mg tablets (5 x 5 mg capsule), orally
Study NCT01110616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Lorazepam
Description: Lorazepam, 2 mg (2 x 1 mg tablet), orally
Study NCT01851642 — intervention group
Intervention type: PROCEDURE
Intervention: Pulmonary function testing.
Description: At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.
Study NCT01851642 — intervention group
Intervention type: DRUG
Intervention: Albuterol inhaler.
Description: At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.
Study NCT01745458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SB-659032
Study NCT01745458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study NCT01047488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: Tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks
Study NCT01047488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
Study NCT01047488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine, pregabalin
Description: Imipramine: tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks Pregabalin: capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
Study NCT01047488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to imipramine 25 mg, 3 or 1 tablet evening, daily, 5 weeks Placebo capsules to pregabalin 75 mg, 2 capsules daily, daily, 5 weeks
Study NCT01039740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine administration for 6 weeks under therapeutic dose
Study NCT06096467 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comprehension Exercise Training
Description: Comprehension exercise: 45\~50 minutes exercise for each session(warm-up, resistive, functional activities and balance exercise, and cool-down)
Study NCT06096467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehension Exercise Training
Description: Comprehension exercise: 45\~50 minutes exercise for each session(warm-up, resistive, functional activities and balance exercise, and cool-down)
Study NCT06096467 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo milk
Description: Placebo milk: 8 g. protein for each serving and provided immediately after the CET session
Study NCT06096467 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplement
Description: Protein Supplement: 40 g. whey protein for each serving and provided immediately after the CET session
Study NCT00494676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High power (57 prism diopter) peripheral prism glasses
Description: All patients will wear two pairs of prism glasses in a crossover design: the high power peripheral prism glasses and sham peripheral prism glasses. Each pair of prism glasses will be worn for four weeks
Study NCT00494676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low power sham peripheral prism glasses
Description: Low power (5 prism dioptre) prism glasses that provide only about 2 degrees of visual field expansion.
Study NCT01110616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo, to match MK3134, and placebo to match Lorazepam
Study NCT04311736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exergame
Description: Cycling on a recumbent cycle ergometer + Virtual Reality Cognitive Training
Study NCT04311736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cycling
Description: Cycling on a recumbent cycle ergometer
Study NCT04311736 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stretching
Description: Stretching exercises
Study NCT03055754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon randomized arm
Description: Endoscopic argon plasma coagulation
Study NCT03055754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: No Endoscopic procedure
Study NCT03333642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenal Ileal Interposition with Sleeve Gastrectomy
Description: Laparoscopic or open Duodenal Ileal Interposition with Sleeve Gastrectomy
Study NCT03151720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine (Xisimin [Test Treatment])
Description: Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
Study NCT03151720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine (Clarityne [Reference Treatment])
Description: Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
Study NCT03754140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol Injection
Description: Sclerotic agent
Study NCT01129362 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pentacel® (DTaP-IPV/Hib)
Description: 0.5 mL dose, Intramuscular
Study NCT01129362 — intervention group
Intervention type: BIOLOGICAL
Intervention: Other Pertussis Vaccines
Description: 0.5 mL, Intramuscular
Study NCT01776762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Individual nutritional therapy
Description: Individual nutritional therapy provided by registered dietician by means of three Home-visits
Study NCT02716675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered by IV infusion; total dose will vary based on participant's weight
Study NCT02716675 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VRC01
Description: Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
Study NCT04906356 — intervention group
Intervention type: GENETIC
Intervention: Genetic sub-study
Description: One time saliva sample collection
Study NCT04256460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy diet, regular exercises and peer support
Description: After assessing the exercise and nutritional status of the participants, health staff in community health centers implemented personalized healthy diet and regular exercises intervention, including coaching on healthy exercises and developing personalized dietary prescriptions for participants. Besides, peer support is implemented as a self management strategy in community health service centers or community self management groups to enhance the behavioral change support for these participants.
Study NCT02809131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polymixin/bacitracin
Description: Antibacterial irrigation
Study NCT02809131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cephalexin, or levofloxacin, or clindamycin
Description: Post operative oral antibiotics
Study NCT02809131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline irrigation
Study NCT04067479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acids
Description: Oral bolus of essential amino acids
Study NCT02535715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 capsules- 2x8mg
Description: Participants who receive this intervention first, then receive either ORMD-0801- 3x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
Study NCT02535715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 capsules- 3x8mg
Description: Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
Study NCT02535715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 capsules- 1x16mg
Description: Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 3x8mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
Study NCT04022187 — intervention group
Intervention type: OTHER
Intervention: Observational study : no intervention
Description: Observational study : no intervention, only exporting data
Study NCT04559191 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous glucose monitoring (CGM)
Description: CGM (FreeStyle Libre Pro®, Abbott, Chicago, Illinoi, the United States)
Study NCT04735822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Belumosudil 40 mg/mL Sequence ABFCED
Description: Oral suspension belumosudil 40 mg/mL in sequence Regimen A, then Regimen B, then Regimen F, then Regimen C, then Regimen E, then Regimen D
Study NCT04735822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Belumosudil 40 mg/mL Sequence BCADFE
Description: Oral suspension belumosudil 40 mg/mL in sequence Regimen B, then Regimen C, then Regimen A, then Regimen D, then Regimen F, then Regimen E
Study NCT04735822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Belumosudil 40 mg/mL Sequence CDBEAF
Description: Oral suspension belumosudil 40 mg/mL in sequence Regimen C, then Regimen D, then Regimen B, then Regimen E, then Regimen A, then Regimen F
Study NCT04735822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Belumosudil 40 mg/mL Sequence DECFBA
Description: Oral suspension of belumosudil 40 mg/mL in sequence Regimen D, then Regimen E, then Regimen C, then Regimen F, then Regimen B, then Regimen A
Study NCT04735822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Belumosudil 40 mg/mL Sequence EFDACB
Description: Oral suspension of belumosudil 40 mg/mL in sequence Regimen E, then Regimen F, then Regimen D, then Regimen A, then Regimen C, then Regimen C
Study NCT04735822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Belumosudil 40 mg/mL Sequence FAEBDC
Description: Oral suspension of belumosudil 40 mg/mL in sequence Regimen F, then Regimen A, then Regimen E, then Regimen B, then Regimen D, then Regimen C
Study NCT04735822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Belumosudil 200 mg Sequence GHI
Description: 1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed)
Study NCT04735822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Belumosudil 200 mg Sequence HIG
Description: 1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed), then Regimen G (tablet)
Study NCT04735822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Belumosudil 200 mg Sequence IGH
Description: 1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen G (tablet), then Regimen H (oral suspension, subject fasted)
Study NCT04735822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Belumosudil 200 mg Sequence IHG
Description: 1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted), then Regimen G (tablet)
Study NCT04735822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Belumosudil 200 mg Sequence GIH
Description: 1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted)
Study NCT04735822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Belumosudil 200 mg Sequence HGI
Description: 1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen G (tablet), then Regimen I (oral suspension; subject fed)
Study NCT04092296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resin infiltration
Description: using infiltrant resin intervene proximal caries
Study NCT04092296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: remineralization
Description: using fluoride to remineralize proximal caries
Study NCT04092296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham
Description: replace resin with water
Study NCT02705521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergames- Laptop and MIcrosoft Kinect
Description: Following surgery each patient will have a set of games for them to play using their affecting shoulder. These games have been designed by physiotherapists and shoulder surgeons to improve the functional range of movement in their shoulder
Study NCT03974087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: 2mA stimulation for 20 minutes
Study NCT03974087 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: 2mA stimulation for 20 minutes
Study NCT01411020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,
Study NCT03685383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosorb removal column in eCPR
Description: In addition to standard treatment in eCPR in the study group a CytoSorb removal column is added to the va-ECMO system for the prevention of post-cardiac arrest syndrome.
Study NCT03685383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard eCPR (va-ECMO)
Description: Standard treatment in eCPR with a established va-ECMO system.
Study NCT02782936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurement of the work of breathing
Description: We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. A gas mask has been used mask (C4, Airboss Defence, Bromont, Canada).~Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Each condition lasted 10 minutes, data of the last 2 minutes at a steady state has been considered for analyses.